Department Research Activities

Research activities of the Department of Dermatology, Zurich University Hospital

Our research activities are primarily focussed on basic, patient-oriented translational, and clinical research in:

  • Dermato-oncology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma, and non-melanoma skin cancers.
  • Immunodermatology, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and severe allergic adverse drug reactions.
  • Allergology, emphasizing on drug and food allergies, and specific immunotherapy.

Dermatologischen Klinik

logo_usz

The Departments Research Groups

Clinical Trials

Highlights

Approx. 50 ongoing clinical trials on new therapeutic approaches in skin disease.

FPFV= First patient first visit
LPLV= Last patient last visit
NOP= Number of patient

Protocol Study title FPFV LPLV NoP PI
Abbott Humira Nicht vorhanden 18/02/2008 07/08/2008 2 Prof. R. Trüeb
Abbott M10-016 "A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874" 13/07/2009 11/05/2011 6 Prof. L. French
Abbott ABT-874-255 Nicht vorhanden 07/07/2008 29/12/2008 8 Prof. R. Trüeb
Abbott ABT-874-255-2 Nicht vorhanden 10/10/2008 02/06/2009 7 Prof. R. Trüeb
AbbottABT-874-255-3 Nicht vorhanden 27/03/2009 19/10/2009 6 Prof. R. Trüeb
Abbvie H13-147 "An Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult and Adolescent Patients with Hidradenitis Suppurativa – UNITE" 02/02/2015 ongoing 3 Prof. L. French
Actelion AC-085A201 "A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administered up to twenty-eight weeks in patients with moderate to severe chronic plaque psoriasis" 02/05/2011 29/03/2012 4 Prof. L. French
ALIGN "ALIGN – Multi-country, cross sectionAL study to determine patient specIfic and General beliefs towards medicatioN and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID)" 19/02/2013 20/02/2013 10 Prof. L. French
Amgen 20120102 "A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1" 15/10/2012 25/08/2015 4 Prof. L. French
CAIN457A2304E1 "A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen" 11/03/2013 ongoing 3 Prof. L. French
CAIN457A3302_OPTIMISE "Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c." 07/01/2016 ongoing 4 Prof. L. French
Celgene PSOR009 "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS" 22/11/2011 06/11/2012 1 Prof. L. French
Centocor-Studie C0743T09 "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis" 31/06/2006 21/02/2011 1 Prof. L. French
Creabilis CT 327 PV 01-09 "A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for Eight Weeks to Patients with Mild to Moderate Psoriasis Vulgaris." 07/07/2010 29/12/2010 5 Prof. L. French
Eli Lilly RHBS "Protocol I1F-MC-RHBS(a) A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis" 10/11/2015 ongoing 6 Prof. L. French
Haemopep Nicht vorhanden 17/03/2008 09/11/2009 25 Prof. R. Trüeb
Hidradenitis M11-810 "A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" 18/02/2013 21/11/2013 6 Prof. L. French
Hidradenitis M12-555 "A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" 06/11/2013 02/06/2016 5 Prof. L. French
IBSA Nicht vorhanden 24/05/2006 25/09/2007 19 Prof. R. Trüeb
IMTM-Studie Nicht vorhanden 05/02/2009 30/06/2011 19 Prof. L. French
Novartis CAIN457A2304 "A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE)" 14/02/2012 18/02/2013 2 Prof. L. French
Novartis HS CJM112X2202 "A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients" 10/07/2015 ongoing 5 Prof. L. French
Pantogar 60+ Nicht vorhanden 03/03/2008 25/02/2010 85 Prof. R. Trüeb
Pyoderma "A PHASE II MULTI CENTER OPEN LABEL PILOT STUDY TO ASSESS A POTENTIAL EFFECT OF AN ANTI-IL-1-? ANTAGONIST IN THE TREATMENT OF PYODERMA GANGRENOSUM" 28/04/2011 21/10/2014 6 Prof. L. French
Remicade (Essex) Nicht vorhanden 23/03/2007 14/09/2007 7 Prof. R. Trüeb
SDNTT "Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg." 29/11/2011 ongoing 195 Prof. L. French
Urticana "A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE CENTER STUDY OF CANAKINUMAB TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE CHRONIC IDIOPATHIC URTICARIA" 15/08/2012 02/12/2013 13 Prof. L. French
Wolff Nicht vorhanden 10/04/2006 07/12/2007 28 Prof. R. Trüeb
Wyeth Nicht vorhanden 27/01/2006 18/01/2007 5 Prof. R. Trüeb